Современные представления об инфекции Clostridium difficile | КМАХ

Современные представления об инфекции Clostridium difficile

Клиническая Микробиология и Антимикробная Химиотерапия. 2002; 4(3):200-232

​ Лобзин Ю.В., Захаренко С.М., Иванов Г.А.
С.difficile антибиотикоассоциированная диарея антибактериальная терапия C.difficile-ассоциированная диарея псевдомембранозный колит
Раздел
Болезни и возбудители
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2002; 4(3):200-232

Аннотация

Clostridium difficile является основным возбудителем нозокомиальной диареи, связанной с назначением антимикробных препаратов. Однако данной проблеме в нашей стране не уделяется достаточного внимания. В настоящем обзоре литературы рассмотрены вопросы эпидемиологии C.difficile-инфекции, особенности взаимодействия C.difficile с макроорганизмом и роль факторов патогенности. Описаны клинические формы C.difficile-ассоциированных болезней: от бессимптомного носительства до псевдомембранозного колита. Дана сравнительная характеристика методов диагностики инфекции C.difficile. Изложены основные современные принципы лечения манифестных форм инфекции. Большое внимание уделено вопросам специфической терапии и проведения мероприятий по восстановлению микробиоценоза кишечника.

  • 1. Garthright W.E., Archer D.I., Kvenberg J.E. Estimates of incidence and cost of intestinal infectious diseases in the United States. Public Health Rep 1988; 103:107-15.
  • 2. Тайц Б.М., Зуева Л.П. Инфекционный контроль в лечебно-профилактических учреждениях. СПб: СПбГМА им. И.И. Мечникова; 1998. с. 295.
  • 3. Frost F., Craun G.F., Calderon R.L. Increasing Hospitalization and Death Possibly Due to Clostridium difficile Diarrheal Disease. Emerg Infect Dis 1998; 4:619-25.
  • 4. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis 1992; 15:573-81.
  • 5. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Diagn Dis 1998; 16:292-307.
  • 6. McFarland L.V., Surawicz C.M., Rubin M., Fekety R., Elmer G.W., Greenberg R.N. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20:43-50.
  • 7. Bartlett J.G . Antibiotic-associated colitis. Dis Mon 1984; 30:1-55.
  • 8. Малов В.А., Бондаренко В.М., Пак С.Г. Роль Clostridium difficile в патологии человека. Журнал микробиол 1996; 1:91-6.
  • 9. Ерюхин И.А., Шляпников С.А., Лебедев В.Ф., Иванов Г.А. Псевдомембранозный колити «кишечный сепсис» – следствие дисбактериоза, вызванного антибиотиками. Вестн хир 156 (2):108-11.
  • 10. Mylonakis E., Ryan E.T., Calderwood S.B. Clostridium difficile-аssociated diarrhea: A review. Arch Intern Med 2001; 161:525-33.
  • 11. Clostridium difficile in England and Wales — weeks 1-26/99. Commun Dis Rep CDR Wkly 1999; 9:366.
  • 12. Wistrom J., Norrby S.R., Myhre E.B., Eriksson S., Granstrom G., Lagergren L., Englund G., Nord C.E., Svenungsson В. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients; a prospective study. J Antimicrob Chemother 2001; 47:43-50.
  • 13. Mayfield J.L., Leet T., Miller J., Mundy L.M. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000;31:995-1000.
  • 14. Finney J.M. Gastroenterostomy for cicatrizing ulcer of the pylorus. Johns Hopkins Hosp Bull 1893; 11:53-5.
  • 15. Bennet I.L., Wood J.S., Yardley H.H. Staphylococcal pseudomembranous enterocolitis in chinchillas: A clinico-pathologic study. Trans Assoc Am Physician 1956; 69:1-16.
  • 16. Dearing W.H., Baggenstoss A.H., Weed L.A. Studies on the relationship of Staphylococcus aureus to pseudomembranous enteritis and to postantibiotic enteritis. Gastroenterology 1960; 38:441-51.
  • 17. Altemeier W.A., Hummel R.P., Hill E.O. Staphylococcal enterocolitis follwing antibiotic therapy. Ann Surg 1963;157:847-58.
  • 18. Fekety R. Staphylococcal diarrhea and enterocolitis. In: Crossley K.B., Archer G.L., eds. The Staphylococci in Human Disease. New York: Churchill Livingstone; 1997. p. 545-63.
  • 19. Lusk R.H., Fekety F.R. Jr., Silva J. Jr., et al. Gastrointestinal side effects of clindamycin and ampicillin therapy. J Infect Dis 1977; 135(Suppl 1):S111-9.
  • 20. Gurwith M.J., Rabin H.R., Love K. Diarrhea associated with clindamycin and ampicillin therapy: Preliminary results of a cooperative study. J Infect Dis 1977; 135(Suppl 1):S104-10.
  • 21. Robertson M.B., Breen K.J., Desmond P.V., et al. Incidence of antibiotic-related diarrhoea and pseudomembranous colitis: A prospective study of linkomycin, clindamycin and ampicillin. Med J Aust 1977; 1:243-6.
  • 22. Tedesco F.J., Barton R.W., Alpers D.H. Clindamycinassociated colitis. Ann Intern Med 1974; 81:429-33.
  • 23. Hafiz S. Clostridium difficile and Its Toxins [dissertation]. Leeds, England, Univ. Leeds; 1974. PhD.
  • 24. Bartlett J.G., Onderdonk A.B., Cisneros R.L., Kasper D.L. Clindmycin-associated colitis due to toxin-producing species of Clostridium difficile in hamsters. J Infect Dis 1977; 136:701-5.
  • 25. Bartlett J.G., Chang T.W., Gurwith M., Gorbach S.L., Onderdonk A.B. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298:531-43.
  • 26. Rifkin G.D., Fekety F.R., Silva J. Jr. Antibiotic-induced colitis: Implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet 1977; 2:1103-6.
  • 27. Larson H.E., Price A.B. Pseudomembranous colitis: Presence of clostridial toxin. Lancet 1977; 2:1312-4.
  • 28. George W.L., Sutter V.L., Citron D. et al. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 1979; 9:214-9.
  • 29. Lyerly D.M., Allen S.D. The clostridia. In: Emmerson A.M., Hawkey P.M., Gillespie S.H., eds. Principles and Practice of Clinical Bacteriology. Chichester: John Wiley & Sons; 1997. p. 599-623.
  • 30. Lai K.K., Melvin Z.S., Menard M.J. et al. Clostridium difficile-associated diarrhea: Epidemiology, risk factors, and infection control. Infect Control Hosp Epidemiol 1997; 18:628-32.
  • 31. Ho M., Yang D., Wyle F.A., Mulligan M.E. Increased incidence of Clostridium difficile-associated diarrhea following decreased restriction of antibiotic use. Clin Infect Dis 1996; 23(Suppl 1):S102-6.
  • 32. Gerding D.N., Johnson S., Peterson L.R., Mulligan M.E., Silva J.Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16:459-77.
  • 33. Foulke G.E., Silva J.Jr. Clostridium difficile in the intensive care unit; management problems and prevention issues. Crit Care Med 1989;17:822-6.
  • 34. Kent К.С., Rubin M.S., Wroblewski L., Hanff P.A., Silen W. The impact of Clostridium difficile on a surgical service: a prospective study of 374 patients. Ann Surg 1998; 227:296-301
  • 35. Delmee M., Vandercam B., Avesani V., Michaux J.L. Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. Eur J Clin Microbiol 1987; 6:623-7.
  • 36. Bender B.S., Bennett R., Laughon B.E., Greenough W.B. 3rd, Gaydos C., Sears S.D., Forman M.S., Bartlett J.G. Is Clostridium difficile endemic in chronic care facilities? Lancet 1986; 2:11-3.
  • 37. Fekety R., Shah A.B. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 209:71-5.
  • 38. Samore M.H., DeGirolami P.C., Tlucko A., Lichtenberg D.A., Melvin Z.A., Karchmer A.W. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994; 18:181-7.
  • 39. Stubbs S.L., Brazier J.S., O’Neill G.L., Duerden B.I. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37:461-3.
  • 40. Kato H., Kato N., Watanabe K., Yamamoto T., Suzuki K., Ishigo S., Kunihiro S., Nakamura I., Killgore G.E., Nakamura S. Analysis of Clostridium difficile Isolates from Nosocomial Outbreaks at Three Hospitals in Diverse Areas of Japan. J Clin Microbiol 2001; 39:1391-5.
  • 41. Van Dijck P., Avesani V., Delmee M. Genotyping of outbreak-related and sporadic isolates of Clostridium difficile belonging to serogroup C. J Clin Microbiol 1996; 34:3049-55.
  • 42. Samore M.H., Bettin K.M., DeGirolamini P.C. et al. Wide diversity of Clostridium difficile types at a tertiary referral hospital. J Infect Dis 1994; 170:615-21.
  • 43. O’Neil G.L., Beaman M.H., Riley T.V. Relapse vs reinfection with Clostridium difficile. Epidemiol Infect 1991; 107:627-35.
  • 44. Wilcox M.H., Fawley W.N. Hospital disinfectants and spore formation by Clostridium difficile. Lancet 2001; 356:1324.
  • 45. Nath S.K., Thornley J.H., Kelly M., Kucera B., On S.L., Holmes B., Costas M. A sustained outbreak of Clostridium difficile in a general hospital: persistence of a toxigenic clone in four units. Infect Control Hosp Epidemiol 1994; 15:382-9.
  • 46. Testore G.P., Pantosti A., Cerquetti M., et al. Evidence for cross-infection in an outbreak of Clostridium difficileassociated diarrhea in surgical unit. J Med Mcirobiol 1988; 26:125-8.
  • 47. Clabots C.R., Peterson L.R., Gerding D.N. Characterization of a nosocomial Clostridium difficile outbreak by using plasmid profile typing and clindamycin susceptibility testing. J Infect Dis 1988; 158:731-6.
  • 48. Johnson S., Gerding D.N. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:1027-36.
  • 49. Nolan N.P., Kelly C.P., Humphreys J.F. et al. An epidemic of pseudomembranous colitis: importance of person to person spread. Gut 1987; 28:1467-73.
  • 50. Clabots C.R., Johnson S., Olson M.M., Peterson L.R., Gerding D.N. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992; 166:561-7.
  • 51. Hall I.C., O’Toole E. Intestinal flora in newborn infants. Am J Dis Child 1935; 49:390-402.
  • 52. Viscidi R., Wiley S., Bartlett J.G. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981; 81:5-9.
  • 53. Eglow R., Pothoulakis C., Itzkowitz S., et al. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest 1992; 90:822-9.
  • 54. Rolfe R.D., Song W. Immunoglobulin and nonimmunoglobulin components of human milk inhibit Clostridium difficile toxin A-receptor binding. J Med Microbiol 1995; 42:10-9.
  • 55. Dallas S.D., Rolfe R.D. Binding of Clostridium difficile toxin A to human milk secretory component. J Med Microbiol 1998; 47:879-88.
  • 56. Kamaras J., Murrell W.G. Intestinal epithelial damage in sids babies and its similarity to that caused by bacterial toxins in the rabbit. Pathology 2001; 33:197-203.
  • 57. Aronsson B., Mollby, Nord C.E. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiologic data from Sweden 1981–1982. J Infect Dis 1985; 151:476-81.
  • 58. Nakamura S., Mikawa M., Takabatake M., et al. Isolation of Clostridium difficile from the feces and antibody in sera of young and elderly adults. Microbiol Immunol 1981; 25:345-51.
  • 59. Thielman N.M. Antibiotic-associated colitis. In: Mandell G.L., Bennett J.E., Dolin R. Principles and Practice of Infectious Diseases. 5th edition. Philadelphia: Churchill Livingstone; 2000. p. 1111-26.
  • 60. Shim J.K., Johnson S., Samore M.H., Bliss D.Z., Gerding D.N. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhea. Lancet 1998; 351:633-6.
  • 61. McFarland L.V., Mulligan M., Kwok R.Y.Y., Stamm W.E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320:204-10.
  • 62. Johnson S., Gerding D.N., Olson M.M., Weiler M.D., Hughes R.A., Clabots C.R., Peterson L.R. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990; 88:137-40.
  • 63. Fekety R., Kim K.H., Brown D., et al. Epidemiology of antibiotic associated colitis: isolation of Clostridium difficile from the hospital environment. Am J Med 1981; 70:906-8.
  • 64. Malamou-Ladas H., O’Farrell S., Nash J.Q., Tabaqchali S. Isolation of Clostridium difficile from patients and the environment of hospital wards. J Clin Pathol 1983; 36:88-92.
  • 65. Kim K.H., Fekety R., Batts D.H., et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981;143:42-50.
  • 66. Simor A.E., Yake S.L., Tsimidis K: Infection due to Clostridium difficile among elderly residents of a longterm care facility. Clin Infect Dis 1993; 17:672-8.
  • 67. Riley T.V., Adams J.E., O’Neil G.L., Bowman R.A. Gastrointestinal carriage of Clostridium difficile in cats and dogs attending veterinary clinics. Epidemiol Infect 1991; 107:659-65.
  • 68. Greenfild C., Aguilar Ramirez J.R., Pounder R.E., et al. Clostridium difficile and inflammatory bowel disease. Gut 1983;24:713-7.
  • 69. Hirschhorn L.R., Tinka Y., Onderdonk A., Lee M-L.T., Platt R. Epidemiology of community-acquired Clostridium difficile associated diarrhea. J Infect Dis 1994; 169:127-33.
  • 70. Pear S., Williamson T., Bettin K., Gerding D.N., Galgiani J.N. Decrease in nosocomial Clostridium difficileassociated diarrhea by restricting clindamycin use. Ann Intern Med 1994; 120:272-7.
  • 71. Anand A., Bashey B., Mir T., Glatt A.E. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994; 89:519-23.
  • 72. Anand A., Glatt A.E. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17:109-13.
  • 73. Emoto M., Kawarabayashi T., Hachisuga M.D., et al. Clostridium difficile colitis associated with cisplatinbased chemotherapy in ovarian cancer patients. Gynecol Oncol 1996; 61:369-72.
  • 74. Grube B.J., Heimbach D.M., Marvin J.A. Clostridium difficile diarrhea in criticaly ill burned patients. Arch Surg 1987; 122:655-61.
  • 75. Aronsson B., Barany P., Nord C.E., et al. Clostridium difficile-associated diarrhea in uremic patients. Eur J Clin Microbiol 1987; 6:352-6.
  • 76. Heard S.R., Wren B., Barnett M.J., et al. Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. Epidemiol Infect 1988; 100:63-72.
  • 77. Pierce P.F. Jr., Wilson R., Silva J.Jr., et al. Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. J Infect Dis 1982; 45:269-74.
  • 78. Buchner A.M., Sonnenberg A. Medical diagnoses and procedures associated with Clostridium difficile colitis. Am J Gastroenterol 2001; 96:766-72.
  • 79. Cheng S.H., Lu J.J., Young T.G., Perng C.L., Chi W.M. Clostridium difficile-associated diseases: comparison of symptomatic infection versus carriage on the basis of risk factors, toxin production, and genotyping results. Clin Infect Dis 1997; 25:157-8.
  • 80. Mody L.R., Smith S.M., Dever L.L. Clostridium difficileassociated diarrhea in a VA medical center: clustering of cases, association with antibiotic usage, and impact on HIV-infected patients. Infect Control Hosp Epidemiol 2001; 22:42-5.
  • 81. Selva O’Callaghan A., Yuste M., Armadansa L., Almirante Gragerab B., San Jose Laporte A., Vilardell Tarres M. Factors for Clostridium difficile-associated diarrhea in elderly patients. A case-control study. Med Clin (Barc) 2000; 115:499-500.
  • 82. McFarland L.V., Surawicz C.M., Stamm W.E. Risk factors for Clostridium difficile carriage and Clostridium difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990; 62:678-84.
  • 83. Goldhill J.M., Rose K., Percy W.H. Effect of antibiotics on epithelial ion transport in the rabbit distal colon in vitro. J Pharm Pharmacol 1996; 48:651-6.
  • 84. Salyers, Abigail A. Pseudomembranous Colitis: A Disease Caused by Antibiotics. In: Salyers, Abigail A. Bacterial pathogenesis: a molecular approach. Washington: American Society for Microbiology; 1994. p. 282-9.
  • 85. Allen S.D., Emery C.L., Siders J.A. Clostridium. In: Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., Yolken R.H., editors. Manual of clinical microbiology. 7th ed. Washington D.C.: American Society for Microbiology; 1999. p. 654-72.
  • 86. Just I., Selzer J., Wilm M., von Eichel-Streiber C., Mann M., Aktories K. Glycosylation of Rho proteins by Clostridium difficile toxin B. Nature 1995; 375: 500-3.
  • 87. Hecht G., Pothoulakis C., LaMont J.T., Madara J.L. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeablity of cultured human intestinal epithelial monolayers. J Clin Invest 1988; 82:1516-24.
  • 88. Nusrat A., von Eichel-Streiber C., Turner J.R., Verkade P., Madara J.L., Parkos C.A. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun 2001; 69:1329-36.
  • 89. Feltis B.A., Wiesner S.M., Kim A.S., Erlandsen S.L., Lyerly D.L., Wilkins T.D., Wells C.L. Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes. Shock 2000; 14:629-34.
  • 90. Hatheway C.L. Toxigenic clostridia. Clin Microbiol Rev 1990; 3:66-98.
  • 91. Seddon S.V., Hemingway I., Borriello S.P. Hydrolytic enzyme production by Clostridium difficile and its relationship to toxin production and virulence in the hamster model. J Med Microbiol 1990; 31:169-74.
  • 92. Cohen S.H., Tang Y.J., Silva J. Jr. Analysis of the Pathogenicity Locus in Clostridium difficile Strains. J Infect Dis 2000; 181:659-63.
  • 93. Mani N., Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci USA 2001; 98:5844-9.
  • 94. Borriello S.P., Wren B.W., Hyde S., et al. Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun 1992; 60:4192-9.
  • 95. Guerrant R.L., Lima A.A.M., Thielman N.M., et al. Diarrhea, demography and cell signaling: Lessons from microbial toxins. Am Clin Climat Assn 1997; 108:149-64.
  • 96. Bartlett J.D. Clostridium difficile-associated diarrhea and colitis. In: Gorbach S.L., Bartlett J.G., Blacklow N.R. Infectious diseases. 2nd edition. Washington D.C.: W.B. Saunders Company; 1998. p. 748-56.
  • 97. Torres J., Jennische E., Lange S., Lonnroth I. Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine. Gut 1990; 31:781-5.
  • 98. Pothoulakis C., Sullivan R., Melnick D.A., Triadafilopoulos G., Gadenne A.S., Meshulam T., LaMont J.T. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest 1988; 81:1741-5.
  • 99. Fonteles M., Fang G., Thielman N.M., et al. Role of platelet activating factor in the inflammatiry and secretory effects of Clostridium difficile toxin A. J Lipid Mediat Cell Signal 1995; 11:133-43.
  • 100. Castagliuolo I., Keates A.C., Qui B., et al. Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci USA 1997; 94:4788-93.
  • 101. Steiner T.S., Flores C.A., Pizarro T.T., Guerrant R.L. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol 1997; 4:719-22.
  • 102. Rocha M.F., Maia M.E., Bezerra L.R., et al. Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: Role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. Infect Immunol 1997; 65:2740-6.
  • 103. Mantyh C.R., McVey D.C., Vigna S.R. Extrinsic surgical denervation inhibits Clostridium difficile toxin A-induced enteritis in rats. Neurosci Lett 2000; 292:95-8.
  • 104. Högenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998; 27:702-70.
  • 105. Barth H., Pfeifer G., Hofmann F., Maier E., Benz R., Aktories К. Low pH-induced formation of ion channels by Clostridium difficile toxin В in target cells. J Biol Chem 2001; 276:10670-6.
  • 106. Rocha M.F., Soares A.M., Ribeiro R.A., Lima A.A. Absence of intestinal secretion on supernatants from macrophages stimulated with Clostridium difficile toxin B on rabbit ileum. Toxicon 2001; 39:335-40.
  • 107. Pothoulakis C., Lamont J.T. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 2001; 280:G178-83.
  • 108. Borriello S.P., Davies H.A., Barclay F.E. Detection of fimbriae amongst strains of Clostridium difficile. FEMS Microbiol Lett 1988; 49:65-7.
  • 109. Hennequin C., Porcheray F., Waligora-Dupriet A.J., Collignon A., Barc M.C., Bourlioux P., Karjalainen Т. GroEL (Hsp60) of Clostridium difficile is involved in cell adherence. Microbiology 2001; 147(Pt 1):87-96.
  • 110. Waligora A.J., Hennequin C., Mullany P., Bourlioux P., Collignon A., Karjalainen T. Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect Immun 2001; 69:2144-53.
  • 111. Karjalainen T., Waligora-Dupriet A.J., Cerquetti M., Spigaglia P., Maggioni A., Mauri P., Mastrantonio P. Molecular and genomic analysis of genes encoding surface-anchored proteins from Clostridium difficile. Infect Immun 2001; 69:3442-6.
  • 112. Tasteyre A., Karjalainen T., Avesani V., Delmee M., Collignon A., Bourlioux P., Barc M.C. Molecular characterization of fliD gene encoding flagellar cap and its expression among Clostridium difficile isolates from different serogroups. J Clin Microbiol 2001; 39:1178-83.
  • 113. Kelly P.J., Peterson L.R.. The role of clinical microbiology laboratory in the management of Clostridium difficile-associated diarrhea. Infect Dis Clin North Am 1993; 7:277-93.
  • 114. Putterman C., Rubinow A. Reactive arthritis associated with Clostridium difficile pseudomembranous colitis. Semin Arthritis Rheum 1993; 22:420-6.
  • 115. Jacobs A., Barnard K., Fishel R., Gradon J.D. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2001; 80:88-101.
  • 116. Sakurai T., Hajiro K., Takakuwa H., Nishi A., Aihara M., Chiba T. Liver abscess caused by Clostridium difficile. Scand J Infect Dis 2001; 33:69-70.
  • 117. Olson M.M., Shanholtzer C.J., Lee J.T. Jr., Gerding D.N. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. Infect Control Hosp Epidemiol 1994; 15:371-81.
  • 118. Kyne L., Warny M., Qamar A., Kelly C.P. Association Between Antibody Response to Toxin A and Protection Against Recurrent Clostridium difficile Diarrhea. Lancet 2001; 357:189-93.
  • 119. Aronsson B., Mollby R., Nord C.E. Diagnosis and epidemiology of Clostridium difficile enterocolitis in Sweden. J Antimicrob Chemother 1984; 14:85-95.
  • 120. Bulusu M., Narayan S., Shetler K., Triadafilopoulos G. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 2000; 95:3137-41.
  • 121. Savola K.L., Baron E.J., Tompkins L.S., Passaro D.J. Fecal leukocyte stain has diagnostic value for outpatients but not inpatients. J Clin Microbiol 2001; 39: 266-9.
  • 122. Boland G.W., Lee M.J., Cats A., Mueller P.R. Pseudomembranous colitis: diagnostic sensitivity of the abdominal plain radiograph. Clin Radiol 1994; 49:473-5.
  • 123. Blickman J.G., Boland G.W., Cleveland R.H., Bramson R.T., Lee M.J. Pseudomembranous colitis: CT findings in children. Pediatr Radiol 1995; 25:S157-9.
  • 124. Kirkpatrick I.D., Greenberg H.M. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy? AJR Am J Roentgenol 2001; 176:635-963.
  • 125. Bergstain J.M., Kramer A., Wittman D.H., Aprahamian C., Quebbeman E.J. Pseudomembranous colitis: how useful is endoscopy? Surg Endosc 1990; 4:217-9.
  • 126. Peterson L.R., Holter J.J., Shanholtzer C.J., Garrett C.R., Gerding D.N. Detection of Clostridium difficile toxins A (enterotoxin) and B (cytotoxin) in clinical specimens. Evaluation of a latex agglutination test. Am J Clin Pathol 1986; 86:208-11.
  • 127. Lyerly D.M., Barroso L.A., Wilkins T.D., et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun 1992; 60:4633-9.
  • 128. Peterson L.R., Olson M.M., Shanholtzer C.J., et al. Results of a prospective, 18-month clinical evaluation of culture, Cytotoxin testing and culturette brand (CDT) latex testing in the diagnosis of Clostridium difficile-associated diarrhea. Diagn Microbial Infect Dis 1988; 10: 85-91.
  • 129. Staneck J.L., Weckbach L.S., Allen S.D., Siders J.A., Gilligan P.H., et al. Multicenter evaluation of four methods for Clostridium difficile detection: ImmunoCard C. difficile, cytotoxin assay, culture, and latex agglutination. J Clin Microbiol 1996; 34:2718-21.
  • 130. Barbut F., Kajzer C., Planas N., et al. Comparison of three enzyme immunoassays, a cytotoxicity assay and toxigenic culture for the diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 1993; 31:963-7.
  • 131. Katz D.A., Bates D.W., Rittenberg E., et al. Predicting Clostridium difficile stool cytotoxin results in hospitalized patients with diarrhea. J Gen Intern Med 1997; 12:57-62.
  • 132. Peterson L.R., Kelly J.P., Nordbrock H.A. Role of culture and toxin detection in laboratory testing for diagnosis of Clostridium difficile-associated diarrhea. Eur J Clin Microbiol Infect Dis 1996; 15:330-6.
  • 133. Mundy L.S., Shanholtzer C.J., Willard K.E., Gerding D.N., Peterson L.R. Laboratory detection of Clostridium difficile: a comparison of media and incubation conditions. Am J Clin Pathol 1994; 103:52-6.
  • 134. Shanholtzer C.J., Willard K.E., Holter J.J., Olson M.M., Gerding D.N., Peterson L.R. Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests. J Clin Microbiol 1992; 30:1837-40.
  • 135. Vanpoucke H., De Baere T., Claeys G., Vaneechoutte M., Verschraegen G. Evaluation of six commercial assays for the rapid detection of Clostridium difficile toxin and/or antigen in stool specimens. Clin Microbiol Infect 2001; 7:55-64.
  • 136. Manabe Y.C., Vinetz J.M., Moore R.D., et al. Clostridium difficile colitis: An efficient clinical approach to diagnosis. Ann Intern Med 1995; 123:835-40.
  • 137. Lozniewski A., Rabaud C., Dotto E., Weber M., Mory F. Laboratory Diagnosis of Clostridium difficile-associated Diarrhea and Colitis: Usefulness of Premier Cytoclone A+B Enzyme Immunoassay for Combined Detection of Stool Toxins and Toxigenic C. difficile Strains. J Clin Microbiol 2001; 39:1996-2008.
  • 138. Sultana Q., Chaudhry N.A., Munir M., Anwar M.S., Tayyab M. Diagnosis of Clostridium difficile antibiotic associated diarrhea culture versus toxin assay. J Pak Med Assoc 2000; 50:246-9.
  • 139. Depitre C., Delmee M., Avesani V., et al. Serogroup F strains of Clostridium difficile produce toxin B but not toxin A. J Med Microbiol 1993; 3:434-41.
  • 140. Sambol S.P., Merrigan M.M., Lyerly D., Gerding D.N., Johnson S. Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun 2000; 68:5480-7.
  • 141. Ridell S., Gilligan P., McMilon L. Evaluation of the ImmunoCard Toxin A membrane EIA for Clostridium difficile toxin A. Proceedings of the 97th General Meeting of the American Society for Microbiology; 1997; Washington, DC: American Society for Microbiology; 1997. p.165.
  • 142. Wren B.W., Clayton C.L., Casstledine N.B., et al. Identification of toxigenic Clostridium difficile strains by using a toxin A gene-specific probe. J Clin Microbiol 1990; 28:1808-12.
  • 143. Phelps C.J., Lyerly D.L., Johnson J.L., et al. Construction and expression of the complete Clostridium difficile toxin A gene in Escherichia coli. Infect Immun 1991; 59:150-3.
  • 144. Kato N., Ou C-Y., Kato H., et al. Identification of toxigenic Clostridium difficile by the polymerase chain reaction. J Clin Microbiol 1991; 29:33-7.
  • 145. Gummerlock P.H., Tang Y.J., Weiss J.B., Silva J. Jr. Specific detection of toxigenic strains of Clostridium difficile in stool specimens. J Clin Microbiol 1993; 31:507-11.
  • 146. Kato N., Ou C-Y., Kato H., et al. Detection of toxigenic Clostridium difficile in stool specimens by the polymerase chain reaction. J Infect Dis 1993; 167:455.
  • 147. Kuhl S.J., Tang Y.J., Navarro L., Gummerlock P.H., Silva J. Jr. Diagnosis and monitoring of Clostridium difficile infections with the polymerase chain reaction. Clin Infect Dis 1993; 16 (Suppl 4):S234-8.
  • 148. Fang F.C., Gerding D.N., Petrson L.R. Diagnosis of Clostridium difficile colitis. Ann Intern Med 1996; 125:515; discussion 516.
  • 149. Bartlett J.G. Treatment of Clostridium difficile colitis. Gastroenterology 1985; 89:1192-5.
  • 150. Teasley D.G., Gerding D.N., Olson M.M., Peterson L.R., Gebhard R.L., Schwartz M.J., Lee J.T. Jr. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet 1983; 2:1043-6.
  • 151. Silva J. Jr, Batts D.H., Fekety R., Plouffe J.F., Rifkin G.D., Baird I. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am J Med 1981; 71:815-22.
  • 152. Антибактериальная терапия: Практическое руководство. Л.С. Страчунский, Белоусов Ю.Б., Козлов С.Н., ред. M; 2000.
  • 153. Peterson L.R., Gerding D.N. Antimicrobial agents in Clostridium difficile-associated intestinal disease. In: Raumbaud J.-C., Ducluzeau R., editors. Clostridium difficile-associated Intestinal Diseases. Paris: Springer Verlag; 1990. p. 115-27.
  • 154. Fekety R., Silva J., Kauffman C., Buggy B., Deery H.G. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86:15-9.
  • 155. Bartlett J.G. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984; 6 (Suppl 1):S235-41.
  • 156. Farthing M.J. Novel targets for the pharmacotherapy of diarrhea: a view for the millennium. J Gastroenterol Hepatol 2000;15:G38-45.
  • 157. Hacek D.M., Bednarz P., Noskin G.A., Zembower T., Peterson L.R. Yield of Vancomycin-Resistant Enterococci and Multidrug-Resistant Enterobacteriaceae from Stools Submitted for Clostridium difficile Testing Compared to Results from a Focused Surveillance Program. J Clin Microbiol 2001; 39:1152-4.
  • 158. Chow A.W., Cheng N., Bartlett K.H. In vitro susceptibility of Clostridium difficile to new beta-lactam and quinolone antibiotics. Antimicrob Agents Chemother 1985; 28:842-4.
  • 159. Levett P.N. Antimicrobial susceptibility of Clostridium difficile determined by disc diffusion and breakpoint methods. J Antimicrob Chemother 1988; 22:167-73.
  • 160. Лекарственные средства: Пособие по фармакотерапии для врачей. В 2 ч. Ч. 2. Минск; 1987. с. 527.
  • 161. Hoverstad T., Carlstedt-Duke B., Lingaas E., Midtvedt T., Norin K.E., Saxerholt H., Steinbakk M. Influence of ampicillin, clindamycin, and metronidazole on faecal excretion of short-chain fatty acids in healthy subjects. Scand J Gastroenterol 1986; 21:621-6.
  • 162. Arabi Y., Dimock F., Burdon D.W., Alexander-Williams J., Keighley M.R. Influence of neomycin and metronidazole on colonic microflora of volunteers. J Antimicrob Chemother 1979; 5:531-7.
  • 163. Johnson S., Homann S.R., Bettin K.M., Quick J.N., Clabots C.R., Peterson L.R., Gerding D.N. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:297-302.
  • 164. Bolton R.P., Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169-72.
  • 165. Ings R.M., McFadzean J.A., Ormerod W.E. The fate of metronidazole and its implications in chemotherapy. Xenobiotica 1975; 5:223-5.
  • 166. Kleinfeld D.I., Sharpe R.J., Donta S.T. Parenteral therapy for antibiotic-associated pseudomembranous colitis. J Infect Dis 1988; 157(2):389.
  • 167. Wenisch C., Parschlk B., Hasenhundl M., et al. Comparison of vancomycin, teicoplanin, metronidazol and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813-8.
  • 168. Young G.P., Ward P.B., Bayley N., Gordon D., Higgins G., Trapani J.A., McDonald M.I., Labrooy J., Hecker R. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985; 89:1038-45.
  • 169. De Lalla F., Nicolin R., Rinaldi E., Scarpellini P., Rigoli R., Manfrin V., Tramarin A. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficileassociated diarrhea. Antimicrob Agents Chemother 1992; 36:2192-6.
  • 170. Dudley M.N., McLaughlin J.C., Carrington G., Frick J., Nightingale C.H., Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med 1986; 146:1101-4.
  • 171. Zimmerman M.J., Bak A., Sutherland L.R. Treatment of Clostridium difficile infection. Aliment Pharmacol Ther 1997:11:1003-12.
  • 172. Wilcox M.H., Fawley W., Freeman J., Brayson J. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2000; 46: 551-6.
  • 173. Wexler H.M., Molitoris E., Molitoris D., Finegold S.M. In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria. J Antimicrob Chemother 2001; 47:467-9.
  • 174. Palace G.P., Lazari P., Norton K. Analysis of the physicochemical interactions between Clostridium difficile toxins and cholestyramine using liquid chromatography with post-column derivatization. Biochim Biophys Acta 2001; 1546:171-84.
  • 175. Mahony D.E., Lim-Morrison S., Bryden L., Faulkner G., Hoffman P.S., Agocs L., Briand G.G., Burford N., Maguire H. Antimicrobial Activities of Synthetic Bismuth Compounds against Clostridium difficile. Antimicrob Agents Chemother 1999; 43:582-8.
  • 176. Castagliuolo I., Karalis K., Valenick L., Pasha A., Nikulasson S., Wlk M., Pothoulakis C. Endogenous corticosteroids modulate Clostridium difficile toxin A-induced enteritis in rats. Am J Physiol Gastrointest Liver Physiol 2001; 280:G539-45.
  • 177. Hasan M.S., Smith J.W. Bacterial Infections of the Colon. Curr Treat Options Gastroenterol 2000; 3:249-63.
  • 178. Oliva S.L., Guglielmo B.J., Jacobs R., PolisV.G. Failure of intravenous vancomycin and intravenous metronidazol to prevent or treat antibiotic-associated pseudomembranous coltis. J Infect Dis 1989; 159:1154-5.
  • 179. Tedesco F., Markham R., Gurwith M., et al. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978; 2:226-8.
  • 180. Pasic M., Jost R., Carrel T., et al. Intracolonic vancomycin for pseudomembranous colitis. N Engl J Med 1993; 329:583.
  • 181. Bublin J.G., Barton T.L. Rectal use of vancomycin. Ann Pharmacother 1994; 28:1357-8.
  • 182. Cohen H., Brocavich J.M. Managing Clostridium difficile colitis in patients who lack oral access. Infect Med 1996; 13:101-9.
  • 183. Lipsett P.A., Samantaray U.K., Tam M.L., et al. Pseudomembranous colitis: A surgical disease? Surgery 1994; 116:491-6.
  • 184. Buggy B.P., Fekety R., Silva J. Jr Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987; 9:155-9.
  • 185. Tedesco F.J., Gordon D., Fortson W.C. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985; 80:867-8.
  • 186. Moncino M.D., Falletta J.M. Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient. Successful control with long-term cholestyramine therapy. Am J Pediatr Hematol Oncol 1992; 14:361-4.
  • 187. Surawicz C.M., McFarland L.V., Greenberg R.N., Rubin M., Fekety R., Mulligan M.E., Garcia R.J., Brandmarker S., Bowen K., Borjal D., Elmer G.W. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31:1012-7.
  • 188. Biller J.A., Katz A.J., FloresA.F., et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995; 21:224-6.
  • 189. Seal D., Borriello S.P., Barclay F., et al. Treatment of relapsing diarrhoeae by administration of a nontoxigenic strain. Eur J Clin Microbiol 1987; 6:51-3.
  • 190. Tjellstrom B., Stenhammar L., Eriksson S., Magnusson K.E. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 1993; 341:701-2.
  • 191. Liacouras C.A., Piccoli D.A. Whole-bowel irrigation as an adjunct to the treatment of cronic, relapsing Clostridium difficile colitis. J Clin Gastroenterol 1996; 22:186-9.
  • 192. Tvede M., Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients. Lancet 1989; 1:1156-60.
  • 193. McFarland L.V., Surawicz C.M., Greenberg R.N., Fekety R., Elmer G.W., et al. A randomized placebocontroled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-8.
  • 194. Leung D.Y., Kelly C.P., Boguniewicz M., Pothoulakis C., LaMont J.T., Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118:633-7.
  • 195. Salcedo J., Keates S., Pothoulakis C., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997; 41:366-70.
  • 196. Marteau P.R., Vrese Md, Cellier C.J., Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Сlin Nutr 2001; 73:430S-6S.
  • 197. Alvarez-Olmos M.I., Oberhelman R.A. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis 2001; 32:1567-76.
  • 198. Forestier C., De Champs C., Vatoux C., Joly B. Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Res Microbiol 2001; 152:167-73.
  • 199. Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999:67:302-7.
  • 200. Hamilton-Miller J.M.T. Living in the «post-antibiotic era»: could the use of probiotics be an effective strategy? Clin Microbiol Inf 1997; 3:2-4.
  • 201. Orrhage K., Sjostedt S., Nord C.E. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother 2000; 46:603-12.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились